Livagen vs Bronchogen: comparing two Khavinson tetrapeptides

Livagen vs Bronchogen comes up constantly in the Khavinson-peptide corner of the research community, usually from someone who picked up both names on the same supplier list and wants to know if they're interchangeable, or if one is simply the better bet. Short answer: they aren't interchangeable at all. Livagen targets the liver and has essentially no peptide-specific evidence behind it, while Bronchogen targets bronchial tissue and carries a real, if animal-only, regeneration signal. If you're choosing between the two, the choice should be driven entirely by which organ you're trying to support, not by some idea that one is a general upgrade on the other.

I get asked about this family a lot because the Khavinson bioregulator peptides (Livagen and Bronchogen among them) are cheap, widely stocked, and marketed with a lot of confidence that the underlying data does not match. I've spent time going through what's actually published on each one, and the gap between the two is bigger than most vendor pages let on.

What each peptide is actually built to do

Livagen (Lys-Glu-Asp-Ala) is aimed at the liver. The claimed mechanism is chromatin decondensation in hepatocytes, essentially loosening up tightly packed DNA so silenced genes can switch back on. That idea comes from a single in-vitro mechanism paper covering the broader Khavinson tetrapeptide family, not a study run on Livagen itself. There is no dedicated Livagen trial, animal or human, anywhere in the record. That's not a knock on the compound so much as an honest statement of where the science currently sits.

Bronchogen (Ala-Asp-Glu-Leu) is aimed at bronchial epithelium, the tissue lining your airways. Here the evidence is thinner than a human trial but thicker than Livagen's: a COPD rat model found reduced lung inflammation and restored bronchial-epithelium structure after treatment, a finding echoed in a related Kuzubova et al. rat study. Separately, an in-vitro paper found the AEDL sequence increases DNA thermostability, which at least pins down that the sequence does something measurable at the molecular level. None of this is human data, and I want to be straight about that rather than let the animal work sound bigger than it is. But an actual disease model with a structural outcome is a meaningfully different evidence tier than a mechanism-only paper borrowed from a sister compound.

If you're weighing this against other peptides in your stack, it's worth reading how I think about building a fat-loss peptide stack around mechanism, because the same logic applies here: match the peptide to the specific job, don't reach for the one with the flashiest name.

Cost and side-effect load: closer than the evidence gap suggests

Both peptides are priced similarly on the wholesale/research market, since they're synthesized the same way and sold in the same small-vial format as the rest of the Khavinson line. Neither has documented serious adverse events in humans, mostly because neither has meaningful human data to draw adverse events from in the first place. The side-effect profile reported informally across the Russian literature and user community for the whole family is mild: occasional injection-site irritation, an early transient headache in some users during the first few days of a cycle.

The bigger risk with either one isn't the molecule, it's what's actually in the vial. Khavinson-family peptides are one of the most commonly counterfeited categories in the research-peptide market, and a thin published record like Livagen's makes it an easy target for a supplier to mislabel or underfill. This is where I tell people to actually read their certificate of analysis rather than trust a label. If you haven't done that before, I wrote a full walkthrough on reading a peptide certificate of analysis that covers exactly what to check before you trust a batch.

Dosing: what's documented versus what people run

Neither peptide has a validated human dose-finding study, so any number here reflects the Khavinson-school protocol convention rather than clinical trial data. What people actually run, across both Livagen and Bronchogen, is a short course of 10 to 20 consecutive days, repeated two to three times per year, at roughly 100 to 200 mcg per day subcutaneously. That's the same cycle shape for both compounds because it comes from the same family convention, not from peptide-specific research. If you're running Livagen for liver support, that's the number. If you're running Bronchogen for airway support, it's the same number, just aimed at a different tissue.

Now the part my lawyer makes me say, and he's right: The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Who each one actually suits

Livagen fits someone specifically interested in hepatic support who understands they're working from a mechanism hypothesis, not a demonstrated effect. I wouldn't steer someone away from trying it if liver support is genuinely their goal, but I also wouldn't want anyone believing there's a body of evidence backing it up, because there isn't one yet.

Bronchogen fits someone dealing with respiratory or bronchial concerns who wants a compound with at least one concrete disease-model result behind it. The COPD rat data doesn't prove human efficacy, but it's a real structural finding in a relevant disease model, which puts Bronchogen a tier above Livagen on evidence quality even though both sit in the same "D, provisional" grade internally.

If your interest in either one overlaps with general immune or tissue-repair goals, it's also worth reading how Bronchogen compares against Thymagen, since that's a more common pairing question than Livagen ever comes up in.

I try to stay evidence-based with peptides, and the honest state of this family is that most of it is still animal or in-vitro work carried by a name and a reputation built in the Russian literature decades ago. That doesn't mean skip it. It means know exactly what you're standing on before you start a cycle, and treat the vendor's sourcing and testing as seriously as you treat the mechanism paper.